Covid19 Members

LATEST

Media Inquiries

United States

Carolyn Posner

Phone: +1 202-281-7345

Email: cposner@usibc.com


India

Priyanka Sethi

Phone: +91 9899487687

Email: psethi@usibc.com


Membership

Ryan Miller

Phone: +1 202-725-8257

Email: rmiller@usibc.com


Michael Ridings

Phone: +1 202-463-3132

Email: mridings@usibc.com


Pfizer

Pfizer in India donated 40,000 N95 masks to healthcare workers, ventilators to hospitals and food packets through NGOs.

Anti-Viral Compound Screening- Pfizer confirmed a lead compound and analogues are potent inhibitors of the SARS-CoV-2 3C-like (3CL) protease, based on the results of initial screening assays. In addition, preliminary data suggest the lead protease inhibitor shows antiviral activity against SARS-CoV-2. Consequently, Pfizer will perform pre-clinical confirmatory studies, including further anti-viral profiling and assessment of the suitability of the lead molecule for IV administration clinically. In parallel, the company is also investing in materials that will accelerate the start of a potential clinical study of the lead molecule to third quarter 2020, three or more months in advance of earlier estimates, subject to positive completion of the pre-clinical confirmatory studies.